Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients

Citations Over TimeTop 10% of 2012 papers

Abstract

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies. We hypothesized that the hepatic lipidosis was due to the structure-based toxicity and later established that it was due to the formation of a thiourea metabolite, 2. Subsequent SAR studies of 1 led to the identification of a pyrazine-based lead analogue 3, lacking the thiazole moiety. In vivo metabolite identification studies, followed by the independent synthesis and profiling of the cyclopentyl keto- and hydroxyl- metabolites of 3, led to the selection of piragliatin, 4, as the clinical lead. Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.

Related Papers

• → Determinant of postprandial triglyceride levels in healthy young adults(2019)9 cited
• → Analysis of the protein products encoded by variant glucokinase transcripts via expression in bacteria(1991)16 cited
• → Zonation of glucokinase in rat liver changes during postnatal development(1993)11 cited
• → Glucokinase Gene Expression and Regulation(1994)7 cited
• Glucokinase and diabetes mellitus(2012)